Navigation Links
Renhuang to Launch New Bio-pharmaceutical Product - Ginseng and Deer Antler Extract
Date:6/29/2010

HARBIN, China, June 29 /PRNewswire-Asia-FirstCall/ -- Renhuang Pharmaceuticals, Inc. (Pink Sheets: RHGP) ("Renhuang" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM"), today announced that the Company plans to launch a new biopharmaceutical product, Ginseng and Deer Antler Extract in August 2010. Renhuang estimates that the new product will generate revenues of RMB 3.0 million (approximately $441,000) in fiscal year 2010.

Ginseng and Deer Antler Extract are popular Chinese medicines and have been used for centuries to nourish the blood and the kidneys, restore the body's energy and increase endurance. It is also believed that the compounds work together to promote longevity. Moreover, TCM practitioners employ the ingredients in Renhuang's Ginseng and Deer Antler Extract to balance the body's "Qi" or vital life force. Renhuang brings the advantages of its GMP-certified modern manufacturing processes and state of the art research and development to this trusted remedy.

"We are excited to further expand our product portfolio with another new high-quality, all-natural bio-pharmaceutical product -- our Ginseng and Deer Antler Extract," commented Mr. Shaoming Li, Chairman and Chief Executive Officer of Renhuang. "This is our third new product announcement in 2010, following the successful launch of Qing Re Jie Du Oral Liquid and the recent development of Compound Schisandra Tablets. These new products highlight our R&D strength and our ability to continually cater to the needs of the rapidly expanding Chinese bio-pharmaceutical market. Since there is no clear market leader in this segment, we expect our Ginseng and Deer Antler Extract to be a positive contributor to our revenue growth. We will support this promising new product with a significant marketing effort and aim to establish it as a product of choice for TCM practitioners and consumers."

ABOUT RENHUANG PHARMACEUTICALS, INC.

Renhuang Pharmaceuticals, Inc. is engaged in the research, development, manufacturing, and distribution of botanical products, bio-pharmaceutical products, and traditional Chinese medicines ("TCM"), in the People's Republic of China. All of the Company's products are produced at its three GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The Company distributes its botanical anti-depression and nerve-regulation products, biopharmaceutical products, and botanical antibiotic and OTC TCMs through its network of over 3,000 distributors and over 70 sales centers across 24 provinces in China. Company Website: http://www.renhuang.com .

Safe Harbor Statement

This press release contains certain statements that may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon management's beliefs, assumptions and expectations of the Company's future operations and economic performance, taking into account the information currently available to management. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties, some of which are not currently known that may cause actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition expressed or implied in any forward-looking statements. These forward-looking statements are based on current plans and expectations and are subject to a number of uncertainties including, but not limited to, the Company's ability to expand its Ginseng and Deer Antler Extract product and achieve its estimated sales estimates, ability to manage expansion of its operations effectively, and other factors detailed in the Company's annual report on Form 10-K and other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented herein.

    For more information, please contact:

    Renhuang Pharmaceuticals, Inc.
     Ms. Portia Tan, IR Contact
     Phone: +86-451-8260-2162
     Email: ir@renhuang.com

    CCG Investor Relations:
     Mr. Mark Collinson, Partner
     Phone: +1-310-954-1343 (Los Angeles)
     Email: mark.collinson@ccgir.com
     Web:   http://www.ccgirasia.com

     Mr. Crocker Coulson, President
     Phone: +1-646-213-1915 (New York)
     Email: crocker.coulson@ccgir.com


'/>"/>
SOURCE Renhuang Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Renhuang Announces Fiscal Year 2010 Guidance
2. Renhuang Announces Price Increase on Shengmai Granules
3. Renhuang Schedules Conference Call to Discuss FY 2010 First Quarter Results
4. Renhuang Pharmaceuticals Announces Continual Improvement in Days Sales Outstanding
5. Renhuang Appoints New Director and Establishes Nominating and Compensation Committee
6. Renhuang Pharmaceuticals Announces Plans to Introduce Qing Re Jie Du Oral Liquid
7. Renhuang Elected as Deputy Chair Unit of Heilongjiang Medical Association
8. Renhuang Pharmaceuticals Exhibits All-Natural Products at the 107th China Import and Export Fair
9. Renhuang Announces Successful Preliminary Review of Its Patent Application for Schisandra Total Lignin Extraction Method
10. Renhuang Appoints PricewaterhouseCoopers to Develop a SOX 404 Compliance Program
11. Renhuang Schedules Conference Call to Discuss FY 2010 Second Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2017)... 2017  Eli Lilly and Company (NYSE: LLY ... to resolve pending patent litigation in the U.S. District Court ... regarding the Cialis ® (tadalafil) unit dose patent. This ... As part of the agreement, Cialis exclusivity is now expected ... "The unit dose patent for Cialis is valid and ...
(Date:7/11/2017)... 11, 2017  Sysmex America, Inc., a leading ... equipment as well as middleware information systems technology, ... make quality assurance easier and more risk free ... known for the innovation that it delivers to ... quality assurance processes to a new level with ...
(Date:7/10/2017)... GAITHERSBURG, Md. , July 10, 2017 ... in non-animal test methods, is the recipient of a ... by the PETA International Science Consortium. The device, which ... be used to expose human lung cells to airborne ... lung. IIVS will use the VITROCELL® system for testing ...
Breaking Medicine Technology:
(Date:7/24/2017)... ... July 24, 2017 , ... The Magic ... “Consumer’s Choice” Award, for favorite sex toy. Created in collaboration with website Kinkly.com, ... to be consumer voted. The Magic Wand Rechargeable won in stiff competition from ...
(Date:7/24/2017)... VA (PRWEB) , ... July 24, 2017 , ... ... Managers, **Presented by FDAnews and MSceppa Consulting **, Aug. 22-23, 2017 – Arlington, ... on Friday, July 28. , Increased FDA scrutiny and growing demands to track ...
(Date:7/24/2017)... ... July 24, 2017 , ... Advanced Dermatology, ... Bellmore, New York, (516) 784-5858. The office opened earlier this summer and is ... Friedman and Fruma Leah Wiederman. , Advanced Dermatology, P.C. founder and medical ...
(Date:7/24/2017)... ... ... “A Short Walk to the Mailbox”: a remarkable memoir of an unconventional courtship. ... Ed Clark is a church music director and choral conductor. He has ... worship leader for over fifty years. He has a master’s degree in church ...
(Date:7/23/2017)... ... 2017 , ... Three experts will be interviewed on Facebook ... & Exhibition, to be held in Denver, CO on July 30-August 3, 2017. ... visit the AAPM Facebook page to watch three speakers present their information and ...
Breaking Medicine News(10 mins):